Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 232, “Long-Term Complications After Splenectomy in Adult Chronic Immune Thrombocytopenia With a Minimum Follow-up of 10 Years: First Results From a Single-Center Case-Control Study in 140 Patients With Primary ITP,” presented by Lan-huong Thai.
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380, “T Cells Engineered with a Chimeric Antigen Receptor (CAR)-Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children With Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD; abstract 381, “Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia,” presented by Daniel W. Lee III, MD; and abstract 382, “CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients With Relapsed, Refractory B-Cell ALL,” presented by Jae H. Park, MD.
Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 403, “A Compendium of Cytogenetic Abnormalities in Myelofibrosis: Molecular and Phenotypic Correlates in 826 Patients;” abstract 406, “Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis;” and abstract 405, “Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project.”
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in MDS and CMML; and sorafenib vs placebo in addition to standard treatment for AML.
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementation of a Heparin-Induced Thrombocytopenia Management Program Reduces the Cost of Diagnostic Testing and Pharmacologic Treatment in an Academic Medical Center,” presented by Caroline Dupre Vaughn, RN.
Matthew Lunning, DO, of the University of Nebraska Medical Center, on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Next-Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pretreated and High-Risk Chronic Lymphocytic Leukemia and B-Cell Lymphoma.”
